<p>Lyell Immunopharma（納斯達克股票代碼：LYEL - 獲取免費報告）在週四發佈的研究報告中被羅伯特·W·貝爾德的投資分析師上調至 “強力買入” 評級，Zacks.com 報道。</p>
<p>LYEL 曾受到多份其他研究報告的關注。華爾街禪在週六的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “賣出”。Zacks Research 在 4 月 7 日的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “強烈賣出”。Citizens Jmp 在 3 月 9 日的研究報告中開始覆蓋 Lyell Immunopharma 的股票，給予 “市場表現優於大盤” 評級，並設定 34.00 美元的目標價。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 Lyell Immunopharma 股票的 “賣出（d-）” 評級。最後，Needham &amp; Company LLC 在 4 月 10 日的研究報告中開始覆蓋 Lyell Immunopharma 的股票，給予 “買入” 評級，並設定 44.00 美元的目標價。一位研究分析師給予該股票 “強力買入” 評級，三位給予 “買入” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價為 43.00 美元。</p>
<p>獲取 <strong>Lyell Immunopharma</strong> 警報：</p>
<p><strong>查看我們對 Lyell Immunopharma 的最新股票分析</strong></p>
<h2>Lyell Immunopharma 股票上漲 5.6%</h2>
<p>納斯達克：LYEL 週四開盤價為 20.83 美元。Lyell Immunopharma 的 12 個月低點為 7.65 美元，12 個月高點為 45.00 美元。該公司的市值為 4.8596 億美元，市盈率為-1.28，貝塔值為-0.05。該公司的 50 日移動平均價格為 22.30 美元，200 日移動平均價格為 23.35 美元。</p>
<p>Lyell Immunopharma（納斯達克股票代碼：LYEL - 獲取免費報告）最後一次公佈財報是在 3 月 12 日，報告顯示該季度每股收益（EPS）為（7.68 美元），低於分析師共識預期的（2.15 美元）5.53 美元。Lyell Immunopharma 的股本回報率為-90.52%，淨利潤率為-762,355.56%。該季度的收入為 0.01 百萬美元，而分析師預期為 0.02 百萬美元。研究分析師平均預計 Lyell Immunopharma 在當前年度將發佈-10.45 的每股收益。</p>
<h2>內部買賣</h2>
<p>在其他新聞中，首席運營官 Stephen J. Hill 在 2 月 11 日的交易中出售了 1,236 股 Lyell Immunopharma 的股票。股票以平均價格 23.39 美元出售，總價值為 28,910.04 美元。出售完成後，首席運營官持有該公司 17,795 股股票，價值 416,225.05 美元。此次交易使其持股減少了 6.49%。該交易在與 SEC 的法律文件中披露，文件可通過此鏈接獲取。此外，首席執行官 Lynn Seely 在 2 月 11 日的交易中出售了 7,455 股 Lyell Immunopharma 的股票。股票以平均價格 23.39 美元出售，總交易額為 174,372.45 美元。出售完成後，首席執行官持有 74,266 股該公司的股票，價值 1,737,081.74 美元。這代表其持股減少了 9.12%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 11,310 股公司股票，價值 264,285 美元。公司內部人士持有公司股票的 22.30%。</p>
<h2>Lyell Immunopharma 的機構交易</h2>
<p>最近，一些對沖基金和其他機構投資者買賣了 LYEL 的股票。GSK plc 在第四季度購買了 Lyell Immunopharma 的新股份，金額為 46,560,000 美元。MWG Caph Ltd 在第四季度購買了 Lyell Immunopharma 的新頭寸，金額約為 31,030,000 美元。ARCH Venture Management LLC 在第三季度增加了對 Lyell Immunopharma 的持股，增幅為 51.5%。ARCH Venture Management LLC 現在擁有 2,759,072 股該公司的股票，價值 44,807,000 美元，在上個季度又購買了 938,438 股。Acadian Asset Management LLC 在第一季度增加了對 Lyell Immunopharma 的持股，增幅為 204.2%。Acadian Asset Management LLC 現在擁有 660,899 股該公司的股票，價值 354,000 美元，在上個季度又購買了 443,614 股。最後，Vanguard Group Inc.在第三季度增加了對 Lyell Immunopharma 的持股，增幅為 76.0%。Vanguard Group Inc.現在擁有 779,004 股該公司的股票，價值 12,651,000 美元，在上個季度又購買了 336,378 股。機構投資者持有公司 66.05% 的股票。</p>
<h2>關於 Lyell Immunopharma</h2>
<p>（獲取免費報告）</p>
<p>Lyell Immunopharma 是一家臨牀階段的生物技術公司，專注於開發針對癌症的下一代 T 細胞療法。利用一個結合了細胞療法、基因編輯和分子發現的專有平台，Lyell 旨在克服治療實體腫瘤的關鍵障礙。該公司的方法集中在工程化 T 細胞，以增強其持久性、功能性和對免疫抑制腫瘤微環境的抵抗力。</p>
<p>該公司的產品線包括多個自體 T 細胞項目，旨在針對黑色素瘤、卵巢癌和胰腺癌等實體惡性腫瘤中的腫瘤相關抗原。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Lyell Immunopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA"/></p>
<p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Lyell Immunopharma 嗎？</h2>
<p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Lyell Immunopharma 並不在名單上。</p>
<p>雖然 Lyell Immunopharma 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LYEL

<p>羅伯特·W·貝爾德將 Lyell Immunopharma（NASDAQ:LYEL）的評級上調至 “強烈買入”。該公司在分析師中獲得了混合評級，包括一項強烈買入、三項買入和兩項賣出。目前，其共識評級為 “適度買入”，目標價為 43.00 美元。該股票開盤價為 20.83 美元，上漲 5.6%，市值為 4.8596 億美元。最近的財報顯示每股虧損（7.68 美元），未能達到預期。內部人士最近出售了股票，機構投資者持有該股票的 66.05%</p>

<p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was upgraded by investment analysts at Robert W. Baird to a &#34;strong-buy&#34; rating in a research note issued on Thursday,Zacks.com reports.</p>
<div class="lb-trans"><p>Lyell Immunopharma（納斯達克股票代碼：LYEL - 獲取免費報告）在週四發佈的研究報告中被羅伯特·W·貝爾德的投資分析師上調至 “強力買入” 評級，Zacks.com 報道。</p>
</div><p>LYEL has been the subject of a number of other research reports. Wall Street Zen cut shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Zacks Research cut shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Tuesday, April 7th. Citizens Jmp initiated coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They issued a &#34;market outperform&#34; rating and a $34.00 price target for the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Finally, Needham &amp; Company LLC began coverage on shares of Lyell Immunopharma in a research note on Friday, April 10th. They set a &#34;buy&#34; rating and a $44.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $43.00.</p>
<div class="lb-trans"><p>LYEL 曾受到多份其他研究報告的關注。華爾街禪在週六的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “賣出”。Zacks Research 在 4 月 7 日的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “強烈賣出”。Citizens Jmp 在 3 月 9 日的研究報告中開始覆蓋 Lyell Immunopharma 的股票，給予 “市場表現優於大盤” 評級，並設定 34.00 美元的目標價。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 Lyell Immunopharma 股票的 “賣出（d-）” 評級。最後，Needham &amp; Company LLC 在 4 月 10 日的研究報告中開始覆蓋 Lyell Immunopharma 的股票，給予 “買入” 評級，並設定 44.00 美元的目標價。一位研究分析師給予該股票 “強力買入” 評級，三位給予 “買入” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價為 43.00 美元。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Lyell Immunopharma</strong> 警報：</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Lyell Immunopharma 的最新股票分析</strong></p>
</div><h2>Lyell Immunopharma Stock Up 5.6%</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 股票上漲 5.6%</h2>
</div><p>NASDAQ:LYEL opened at $20.83 on Thursday. Lyell Immunopharma has a 12-month low of $7.65 and a 12-month high of $45.00. The firm has a market capitalization of $485.96 million, a PE ratio of -1.28 and a beta of -0.05. The firm has a 50-day moving average price of $22.30 and a 200 day moving average price of $23.35.</p>
<div class="lb-trans"><p>納斯達克：LYEL 週四開盤價為 20.83 美元。Lyell Immunopharma 的 12 個月低點為 7.65 美元，12 個月高點為 45.00 美元。該公司的市值為 4.8596 億美元，市盈率為-1.28，貝塔值為-0.05。該公司的 50 日移動平均價格為 22.30 美元，200 日移動平均價格為 23.35 美元。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($7.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.15) by ($5.53). Lyell Immunopharma had a negative return on equity of 90.52% and a negative net margin of 762,355.56%.The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. On average, research analysts expect that Lyell Immunopharma will post -10.45 EPS for the current year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（納斯達克股票代碼：LYEL - 獲取免費報告）最後一次公佈財報是在 3 月 12 日，報告顯示該季度每股收益（EPS）為（7.68 美元），低於分析師共識預期的（2.15 美元）5.53 美元。Lyell Immunopharma 的股本回報率為-90.52%，淨利潤率為-762,355.56%。該季度的收入為 0.01 百萬美元，而分析師預期為 0.02 百萬美元。研究分析師平均預計 Lyell Immunopharma 在當前年度將發佈-10.45 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, COO Stephen J. Hill sold 1,236 shares of Lyell Immunopharma stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the completion of the sale, the chief operating officer owned 17,795 shares in the company, valued at $416,225.05. The trade was a 6.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Lynn Seely sold 7,455 shares of Lyell Immunopharma stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the completion of the sale, the chief executive officer owned 74,266 shares of the company's stock, valued at $1,737,081.74. This represents a 9.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,310 shares of company stock worth $264,285 in the last ninety days. Company insiders own 22.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席運營官 Stephen J. Hill 在 2 月 11 日的交易中出售了 1,236 股 Lyell Immunopharma 的股票。股票以平均價格 23.39 美元出售，總價值為 28,910.04 美元。出售完成後，首席運營官持有該公司 17,795 股股票，價值 416,225.05 美元。此次交易使其持股減少了 6.49%。該交易在與 SEC 的法律文件中披露，文件可通過此鏈接獲取。此外，首席執行官 Lynn Seely 在 2 月 11 日的交易中出售了 7,455 股 Lyell Immunopharma 的股票。股票以平均價格 23.39 美元出售，總交易額為 174,372.45 美元。出售完成後，首席執行官持有 74,266 股該公司的股票，價值 1,737,081.74 美元。這代表其持股減少了 9.12%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 11,310 股公司股票，價值 264,285 美元。公司內部人士持有公司股票的 22.30%。</p>
</div><h2>Institutional Trading of Lyell Immunopharma</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of LYEL. GSK plc bought a new stake in shares of Lyell Immunopharma in the 4th quarter worth $46,560,000. MWG Caph Ltd purchased a new position in shares of Lyell Immunopharma in the 4th quarter worth about $31,030,000. ARCH Venture Management LLC boosted its holdings in shares of Lyell Immunopharma by 51.5% in the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company's stock worth $44,807,000 after buying an additional 938,438 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Lyell Immunopharma by 76.0% in the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company's stock worth $12,651,000 after buying an additional 336,378 shares during the last quarter. Institutional investors own 66.05% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些對沖基金和其他機構投資者買賣了 LYEL 的股票。GSK plc 在第四季度購買了 Lyell Immunopharma 的新股份，金額為 46,560,000 美元。MWG Caph Ltd 在第四季度購買了 Lyell Immunopharma 的新頭寸，金額約為 31,030,000 美元。ARCH Venture Management LLC 在第三季度增加了對 Lyell Immunopharma 的持股，增幅為 51.5%。ARCH Venture Management LLC 現在擁有 2,759,072 股該公司的股票，價值 44,807,000 美元，在上個季度又購買了 938,438 股。Acadian Asset Management LLC 在第一季度增加了對 Lyell Immunopharma 的持股，增幅為 204.2%。Acadian Asset Management LLC 現在擁有 660,899 股該公司的股票，價值 354,000 美元，在上個季度又購買了 443,614 股。最後，Vanguard Group Inc.在第三季度增加了對 Lyell Immunopharma 的持股，增幅為 76.0%。Vanguard Group Inc.現在擁有 779,004 股該公司的股票，價值 12,651,000 美元，在上個季度又購買了 336,378 股。機構投資者持有公司 66.05% 的股票。</p>
</div><h2>About Lyell Immunopharma</h2>
<div class="lb-trans"><h2>關於 Lyell Immunopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.</p>
<div class="lb-trans"><p>Lyell Immunopharma 是一家臨牀階段的生物技術公司，專注於開發針對癌症的下一代 T 細胞療法。利用一個結合了細胞療法、基因編輯和分子發現的專有平台，Lyell 旨在克服治療實體腫瘤的關鍵障礙。該公司的方法集中在工程化 T 細胞，以增強其持久性、功能性和對免疫抑制腫瘤微環境的抵抗力。</p>
</div><p>The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.</p>
<div class="lb-trans"><p>該公司的產品線包括多個自體 T 細胞項目，旨在針對黑色素瘤、卵巢癌和胰腺癌等實體惡性腫瘤中的腫瘤相關抗原。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Lyell Immunopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LYEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Lyell Immunopharma 嗎？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Lyell Immunopharma 並不在名單上。</p>
</div><p>While Lyell Immunopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Lyell Immunopharma 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Robert W. Baird to Strong-Buy Rating

Market Beat

Lyell Immunopharma（納斯達克股票代碼：LYEL）被 Robert W. Baird 上調至強力買入評級